Neurology
-
Randomized Controlled Trial Multicenter Study
Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant.
To assess the utility of orexin receptor antagonism as a novel approach to treating insomnia. ⋯ This study provides Class I evidence that suvorexant improves sleep efficiency over 4 weeks in nonelderly adult patients with primary insomnia.
-
Randomized Controlled Trial Multicenter Study
Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial.
To evaluate the efficacy and safety of 18 months of tafamidis treatment in patients with early-stage V30M transthyretin familial amyloid polyneuropathy (TTR-FAP). ⋯ This study provides Class II evidence that 20 mg tafamidis QD was associated with no difference in clinical progression in patients with TTR-FAP, as measured by the NIS-LL and the Norfolk QOL-DN score. Secondary outcomes demonstrated a significant delay in peripheral neurologic impairment with tafamidis, which was well tolerated over 18 months.
-
Randomized Controlled Trial Multicenter Study
A double-blind, randomized, controlled study of botulinum toxin type A in MS-related tremor.
To evaluate the safety and efficacy of botulinum toxin type A in disabling multiple sclerosis (MS)-related upper limb tremor. ⋯ This study provides Class III evidence that targeted injection of botulinum toxin type A is associated with significant improvement in MS-related upper limb tremor.
-
Randomized Controlled Trial Multicenter Study
Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized phase II trial.
To evaluate teriflunomide as add-on therapy to ongoing stable-dosed interferon-β (IFNβ) in patients with relapsing forms of multiple sclerosis (RMS). ⋯ This study provides Class II evidence that teriflunomide, 7 and 14 mg, added to IFNβ, is safe. The T1-Gd lesion burden was significantly reduced with both teriflunomide doses.
-
Randomized Controlled Trial Multicenter Study
Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease.
To evaluate the efficacy and tolerability of lubiprostone (Amitiza) for constipation in Parkinson disease (PD) in a double-blind, randomized, controlled study. ⋯ In this randomized controlled trial, lubiprostone seemed to be well tolerated and effective for the short-term treatment of constipation in PD.